Literature DB >> 29664715

Late Infection-Related Mortality in Asplenic Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.

Brent R Weil1, Arin L Madenci1, Qi Liu1, Rebecca M Howell1, Todd M Gibson1, Yutaka Yasui1, Joseph P Neglia1, Wendy M Leisenring1, Susan A Smith1, Emily S Tonorezos1, Danielle N Friedman1, Louis S Constine1, Christopher L Tinkle1, Lisa R Diller1, Gregory T Armstrong1, Kevin C Oeffinger1, Christopher B Weldon1.   

Abstract

Purpose Infection-related outcomes associated with asplenia or impaired splenic function in survivors of childhood cancer remains understudied. Methods Late infection-related mortality was evaluated in 20,026 5-year survivors of childhood cancer (diagnosed < 21 years of age from 1970 to 1999; median age at diagnosis, 7.0 years [range, 0 to 20 years]; median follow-up, 26 years [range, 5 to 44 years]) using cumulative incidence and piecewise-exponential regression models to estimate adjusted relative rates (RRs). Splenic radiation was approximated using average dose (direct and/or indirect) to the left upper quadrant of the abdomen (hereafter, referred to as splenic radiation). Results Within 5 years of diagnosis, 1,354 survivors (6.8%) had a splenectomy and 9,442 (46%) had splenic radiation without splenectomy. With 62 deaths, the cumulative incidence of infection-related late mortality was 1.5% (95% CI, 0.7% to 2.2%) at 35 years after splenectomy and 0.6% (95% CI, 0.4% to 0.8%) after splenic radiation. Splenectomy (RR, 7.7; 95% CI, 3.1 to 19.1) was independently associated with late infection-related mortality. Splenic radiation was associated with increasing risk for late infection-related mortality in a dose-response relationship (0.1 to 9.9 Gy: RR, 2.0; 95% CI, 0.9 to 4.5; 10 to 19.9 Gy: RR, 5.5; 95% CI, 1.9 to 15.4; ≥ 20 Gy: RR, 6.0; 95% CI, 1.8 to 20.2). High-dose alkylator chemotherapy exposure was also independently associated with an increased risk of infection-related mortality (RR, 1.9; 95% CI, 1.1 to 3.4). Conclusion Splenectomy and splenic radiation significantly increase risk for late infection-related mortality. Even low- to intermediate-dose radiation exposure confers increased risk, suggesting that the spleen is highly radiosensitive. These findings should inform long-term follow-up guidelines for survivors of childhood cancer and should lead clinicians to avoid or reduce radiation exposure involving the spleen whenever possible.

Entities:  

Mesh:

Year:  2018        PMID: 29664715      PMCID: PMC5978467          DOI: 10.1200/JCO.2017.76.1643

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  35 in total

Review 1.  Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force.

Authors:  John M Davies; Michael P N Lewis; Jennie Wimperis; Imran Rafi; Shamez Ladhani; Paula H B Bolton-Maggs
Journal:  Br J Haematol       Date:  2011-11       Impact factor: 6.998

Review 2.  Pediatric cancer survivorship research: experience of the Childhood Cancer Survivor Study.

Authors:  Wendy M Leisenring; Ann C Mertens; Gregory T Armstrong; Marilyn A Stovall; Joseph P Neglia; Jennifer Q Lanctot; John D Boice; John A Whitton; Yutaka Yasui
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

3.  Preventing and treating infections in children with asplenia or hyposplenia.

Authors:  Marina I Salvadori; Victoria E Price
Journal:  Paediatr Child Health       Date:  2014-05       Impact factor: 2.253

4.  Survivors of childhood cancer in the United States: prevalence and burden of morbidity.

Authors:  Siobhan M Phillips; Lynne S Padgett; Wendy M Leisenring; Kayla K Stratton; Ken Bishop; Kevin R Krull; Catherine M Alfano; Todd M Gibson; Janet S de Moor; Danielle Blanch Hartigan; Gregory T Armstrong; Leslie L Robison; Julia H Rowland; Kevin C Oeffinger; Angela B Mariotto
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-04       Impact factor: 4.254

5.  Septicemia and meningitis in children splenectomized for hodgkin's disease.

Authors:  R R Chilcote; R L Baehner; D Hammond
Journal:  N Engl J Med       Date:  1976-10-07       Impact factor: 91.245

6.  Systemic pneumococcal disease after staging splenectomy for Hodgkin's disease 1969-1980 without pneumococcal vaccine protection: a follow-up study 1994.

Authors:  A Foss Abrahamsen; E A Høiby; E Hannisdal; O G Jørgensen; H Holte; V Hasseltvedt; H Høst
Journal:  Eur J Haematol       Date:  1997-02       Impact factor: 2.997

7.  Radiation-induced dose-dependent changes of the spleen following postoperative chemoradiotherapy for gastric cancer.

Authors:  Anouk Kirsten Trip; Karolina Sikorska; Johanna W van Sandick; Maarten Heeg; Annemieke Cats; Henk Boot; Edwin Petrus Marianus Jansen; Marcel Verheij
Journal:  Radiother Oncol       Date:  2015-08-04       Impact factor: 6.280

Review 8.  Postsplenectomy sepsis and its mortality rate: actual versus perceived risks.

Authors:  R J Holdsworth; A D Irving; A Cuschieri
Journal:  Br J Surg       Date:  1991-09       Impact factor: 6.939

9.  Infection among 210 patients with surgically staged Hodgkin's disease.

Authors:  D D Coker; D M Morris; J J Coleman; S C Schimpff; P H Wiernik; E G Elias
Journal:  Am J Med       Date:  1983-07       Impact factor: 4.965

Review 10.  Immunization after the elective end of antineoplastic chemotherapy in children.

Authors:  Francesca Fioredda; Michaela Cavillo; Laura Banov; Alessandro Plebani; Anna Timitilli; Elio Castagnola
Journal:  Pediatr Blood Cancer       Date:  2009-02       Impact factor: 3.167

View more
  6 in total

1.  Adaptations to a Generalized Radiation Dose Reconstruction Methodology for Use in Epidemiologic Studies: An Update from the MD Anderson Late Effect Group.

Authors:  Rebecca M Howell; Susan A Smith; Rita E Weathers; Stephen F Kry; Marilyn Stovall
Journal:  Radiat Res       Date:  2019-06-18       Impact factor: 2.841

Review 2.  Immune function in childhood cancer survivors: a Children's Oncology Group review.

Authors:  Gregory M T Guilcher; Linda Rivard; Jennifer T Huang; Nicola A M Wright; Lynette Anderson; Hesham Eissa; Wendy Pelletier; Shanti Ramachandran; Tal Schechter; Ami J Shah; Ken Wong; Eric J Chow
Journal:  Lancet Child Adolesc Health       Date:  2021-02-16

3.  Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients.

Authors:  Simone de Vries; Michael Schaapveld; Cécile P M Janus; Laurien A Daniëls; Eefke J Petersen; Richard W M van der Maazen; Josée M Zijlstra; Max Beijert; Marten R Nijziel; Karijn M S Verschueren; Leontien C M Kremer; Anna M van Eggermond; Pieternella J Lugtenburg; Augustinus D G Krol; Judith M Roesink; Wouter J Plattel; Dick Johan van Spronsen; Gustaaf W van Imhoff; Jan Paul de Boer; Berthe M P Aleman; Flora E van Leeuwen
Journal:  J Natl Cancer Inst       Date:  2021-06-01       Impact factor: 13.506

4.  Estimated clinical benefit of combining highly conformal target volumes with Volumetric-Modulated Arc Therapy (VMAT) versus conventional flank irradiation in pediatric renal tumors.

Authors:  Joeri Mul; Enrica Seravalli; Mirjam E Bosman; Cornelis P van de Ven; Annemieke S Littooij; Martine van Grotel; Marry M van den Heuvel-Eibrink; Geert O Janssens
Journal:  Clin Transl Radiat Oncol       Date:  2021-05-03

5.  Nanopore-based metagenomic sequencing for the rapid and precise detection of pathogens among immunocompromised cancer patients with suspected infections.

Authors:  Qingmei Deng; Yongqing Cao; Xiaofeng Wan; Bin Wang; Aimin Sun; Huanzhong Wang; Yunfei Wang; Hongzhi Wang; Hongcang Gu
Journal:  Front Cell Infect Microbiol       Date:  2022-09-20       Impact factor: 6.073

6. 

Authors:  Hans-Jürgen Laws; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Maximilian Christopeit; Jane Hecht; Ulrich Heininger; Inken Hilgendorf; Winfried Kern; Kerstin Kling; Guido Kobbe; Wiebe Külper; Thomas Lehrnbecher; Roland Meisel; Arne Simon; Andrew Ullmann; Maike de Wit; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-05       Impact factor: 1.513

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.